Loading
Used as first treatment, dabrafenib plus trametinib shrank tumours in almost two thirds of patients with BRAF V600E-mutant lung cancer and controlled the disease for over a year, supporting its use before chemotherapy.
First-line cohort of the phase 2 multicohort study: 36 patients with untreated BRAF V600E-mutant metastatic non-small-cell lung cancer received dabrafenib plus trametinib.
Objective response was 64 percent with a median progression-free survival of 10.9 months and median overall survival of 24.6 months at the initial report; updated analyses showed durable benefit.
BRAF plus MEK inhibition is a standard first-line option for BRAF V600E lung cancer, with chemo-immunotherapy as the alternative or subsequent line.
Shares BRAF V600E-mutant non-small-cell lung cancer, Dabrafenib, Trametinib, The Lancet Oncology.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares BRAF V600E-mutant non-small-cell lung cancer, Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/